司美格鲁肽去年卖了2508亿元，今年要面临仿制药低价挑战

Core Insights - Novo Nordisk's flagship product, semaglutide, achieved total sales of 228.29 billion Danish Krone (approximately 250.84 billion yuan) in the last year, with a year-on-year growth of over 10% [1] - The company reported a total revenue of 309.06 billion Danish Krone, a 6% increase year-on-year, with a net profit of 102.43 billion Danish Krone, reflecting a 1% growth [2] - The company faces significant challenges this year as the core compound patent for semaglutide will expire in some international markets, including China, on March 20 [2] Product Performance - The sales breakdown for semaglutide includes: - Ozempic (diabetes version) with sales of 127.09 billion Danish Krone - Wegovy (weight loss version) with sales of 79.11 billion Danish Krone - Oral semaglutide (diabetes version) with sales of 22.09 billion Danish Krone [1] - In the Chinese market, the three series of semaglutide products achieved a total sales of 6.81 billion Danish Krone (approximately 7.49 billion yuan) [2] Market Challenges - The company has lowered its overall performance expectations for this year, anticipating a revenue decline of 5% to 13% for 2026, significantly exceeding market expectations [2] - There are currently 10 applications for semaglutide generics filed in the Chinese market, with an additional 11 in Phase III clinical trials [2] Strategic Responses - In response to the patent expiration challenge, the company has launched an oral GLP-1 weight loss drug, Wegovy, which was approved in December last year and has seen a weekly prescription volume of approximately 50,000 since its U.S. launch [3] - The company is also working on stronger GLP-1 weight loss drugs, having submitted new drug applications for a 7.2 mg injection of semaglutide and CagriSema, a combination of cagrilintide and semaglutide [3] - Clinical trials for CagriSema have shown significant weight loss results, with a 22.7% reduction in weight over 68 weeks [3]